Experimental/Investigational/Unproven
Customize your policy alerts
Sign up for wellfleet Policy GL-016 alerts
Get alerted when Policy GL-016 changes without checking for updates manually.
Monitor payer policy activity
This payment guideline governs Wellfleet reimbursement for medical procedures, equipment, medications, testing, and cosmetic procedures identified as experimental, investigational, or unproven. It applies to claims under applicable Wellfleet plans and requires review of services that may fall within the E/I/U category.
No material clinical or coverage changes in this revision.
Experimental, Investigational, and Unproven Coverage Criteria
Experimental/Investigational/Unproven determination
A service is considered experimental, investigational, or unproven when ANY of the following apply:
E/I/U criteria
- Regulatory approval criterion: The service does not have unrestricted market approval from the Food and Drug Administration (FDA) or final approval from any other governmental regulatory body.
- Evidence criterion: There is insufficient or inconclusive medical and scientific evidence to evaluate the service's therapeutic value.
- Alternative-treatment criterion: The service is not medically necessary and a safe and medically accepted alternative is available.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.